Evidence map›Paper›PMID 17004125›Full record

Trial reportJournal of pharmacokinetics and pharmacodynamics2007

Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.

Smita A Kshirsagar, Terrence F Blaschke, Lewis B Sheiner, M Krygowski, Edward P Acosta, Davide Verotta

Abstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of pharmacokinetics and pharmacodynamics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Smita A KshirsagarDepartment of Medicine, Stanford University Medical Center, Stanford, CA, USA.
Terrence F Blaschke
Lewis B Sheiner
M Krygowski
Edward P Acosta
Davide Verotta

Funding

WOMEN'S HEALTH AGENDAU01AI032775 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, MICHAEL S. · 1992 to 2007
$12.9M
Modeling Complex Pharmacokinetics and PharmacodynamicsR01AI050587 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VEROTTA, DAVIDE · 2002 to 2011
$2.3M
TRAINING PROGRAM IN CLINICAL PHARMACOLOGYT32GM007065 · NIGMS · STANFORD UNIVERSITY · PI BLASCHKE, TERRENCE FRANCIS · 1985 to 2003
$603k
NIAID NIH HHS AI32775NIAID NIH HHS AI50587NIGMS NIH HHS T32GM07065
6 · The paper itself

Abstract

Data from clinical trials present numerous problems for the data analyst. These include non-compliance with the prescribed dosing regimen and inaccurate recollection of dosing history by patients as well as mistakes in recording data. Several methods have been proposed to address these issues. One such technique by Lu et al. (Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J. Pharmacokinet. Pharmacodyn. 28:343-362 (2001)) identifies occasions in pharmacokinetic (PK) data where the preceding dosing history is likely to be unreliable. We used this method, implemented in the software program NONMEM (beta) VI, to clean a dataset containing indinavir (IDV) plasma concentrations from HIV-1 infected patients. The data was also cleaned by inspection in Microsoft Excel using clinical PK criteria. A one-compartment model with first order absorption and elimination was fit to both sets of cleaned data. IDV population PK parameters obtained from these analyses were similar to those reported previously. It is established that IDV nephrotoxicity is related to high IDV exposure. However, no relationships were found between any PK parameters and nephrotoxicity in the "compliance cleaned" dataset. In the "PK cleaned" dataset, the oral clearance and apparent volume were lower by 9.1% and 6.6%, respectively in patients with any type of nephrotoxicity and the maximum IDV concentration (C(max)) was 12.1% higher. In patients suffering from nephrolithiasis in particular, C(max) was 15.5% higher. Accordingly, the use of the non-compliance detection method did not improve the reliability of our dataset over the usual method of applying clinical criteria. In fact, analyses on the compliance-cleaned dataset missed some exposure-toxicity relationships. Thus, automated methods must be tested rigorously with 'real life' datasets, used with caution, and always in conjunction with clinical reasoning to avoid overlooking a signal in noisy data.

Indexed as

Data Interpretation, StatisticalHIV-1AdultDatabases as TopicFemaleHIV InfectionsHIV Protease InhibitorsHumansIndinavirKidney DiseasesMaleModels, BiologicalPatient ComplianceReproducibility of ResultsResearch DesignSoftwareHIV Protease InhibitorsIndinavir

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.